ALK-Abelló
ALK releases its annual report 2014
DGAP-News: ALK-Abelló 2015-02-09 / 08:00 --------------------------------------------------------------------- Copenhagen, 2015-02-09 08:00 CET (GLOBE NEWSWIRE) -- ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF) achieved one of its best-ever results in 2014. Total revenue, including partner income, was DKK 2,433 million (2,244) and EBITDA before special items amounted to DKK 453 million (258). 2014 also saw important progress towards ALK's goal of globalising its SLIT-tablet portfolio: In North America, Merck launched the first two SLIT-tablets, GRASTEK(R) and RAGWITEK(R) and initiated the final stage of clinical development for the SLIT-tablet for house dust mite (HDM) allergy. In Japan, Torii advanced the development of the SLIT-tablet for Japanese cedar pollen allergy to the final stage of clinical development and submitted its own registration application for the SLIT-tablet for HDM allergy. In Europe, ALK submitted a registration application for its most important product, the SLIT-tablet for HDM allergic rhinitis and allergic asthma. Moreover, ALK has entered into a strategic partnership with Abbott for Russia and a collaboration with Eddingpharm in China. The Board of Directors proposes a dividend of DKK 5 per share to the annual general meeting. See page 4 in the attached annual report for highlights of Q4 and full-year 2014 and a summary of the 2015 outlook. Audio cast Today, ALK hosts a meeting for analysts and institutional investors at 12.30 p.m. (CET) at which Management will review the financial results, the outlook and answer questions. The meeting will be audio cast on www.alk-abello.com/investor. Participants in the audio cast are kindly requested to call in before 12.25 p.m. (CET). Danish participants should dial in on tel. +45 7025 2300 or +45 7025 6700 and international participants should dial in on tel. +44 208 817 9311. Please use the following Audio Passcode: 8181 5130. The audio cast is available live on our website, where the related presentation will be available shortly before the meeting begins. ALK-Abelló A/S For further information please contact: Jens Bager, President and CEO, tel. +45 4574 7576 Investor Relations: Per Plotnikof, tel. +45 4574 7527, mobile +45 2261 2525 Press: Martin Barlebo, tel. +45 4574 7901, mobile +45 2064 1143 News Source: NASDAQ OMX --------------------------------------------------------------------- 2015-02-09 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------- Language: English Company: ALK-Abelló Denmark ISIN: DK0060027142 End of News DGAP News-Service --------------------------------------------------------------------- 320795 2015-02-09
Aktuelle News
Aktuelle Berichte
Keine Berichte gefunden
Anstehende Events
Keine Events gefunden
Webcasts
Keine Webcasts gefunden